FDA approves GlaxoSmithKline's Votrient for soft tissue sarcomas

Drug approved for STS in patients who have previously had chemotherapy

PHILADELPHIA — The Food and Drug Administration has approved a drug made by GlaxoSmithKline for certain cancer patients.

GSK announced the FDA approval of Votrient (pazopanib) for patients with soft tissue sarcoma who have received prior chemotherapy.

"It is such a great moment to bring forth this treatment option for patients, as it represents one of the few new medical options to be provided to patients with advanced soft tissue sarcoma over the last 30 years," GSK Oncology president Paolo Paoletti said.

Soft tissue sarcomas are a group of rare cancers that affect the mesenchymal cells, which give rise to soft tissues, such as muscles, nerves, fat, blood vessels and others. The incidence of STS was 10,980 in 2011, according to the American Cancer Society.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.